All News

The annual Extraordinary Healer event celebrates oncology nurses nominated for their compassion, expertise and helpfulness.

The FDA has approved Zynlonta (loncastuximab tesirine-lpyl) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

The Cancer Support Community's Biomarker Testing Tool can help identify which targeted therapy should be used for treatment in patients with lung cancer.

A patient discusses her experiences with long-term side effects from cancer treatment and details her frustration with the lack of focus on chemotherapy-induced peripheral neuropathy in patients with advanced cancer.

From a college student who survived lymphoma biking 4,000 miles for charity to the death of “Harry Potter” actress Helen McCrory, here’s what’s happening in the cancer landscape this week.

In patients with resected high-risk stage 3 cutaneous melanoma, distant metastasis-free survival at 3.5 years was 65.3% in patients treated with Keytruda compared with 49.4% in those treated with placebo, which was also consistent in patients with PD-L1-positive tumors.

Final analysis of a phase 3 study demonstrates a tolerable toxicity profile for Gazvya in combination with chemotherapy for patients with ether first-line or relapsed/refractory chronic lymphocytic leukemia.

Recent data found an association between higher BMI and better overall survival among patients with metastatic renal cell carcinoma who were treated with immune checkpoint inhibitors.

Jemperli (dostarlimab) received accelerated approval from the Food and Drug Administration for the treatment of patients with recurrent or advanced endometrial cancer whose disease has progressed on, or following, prior treatment with a platinum-containing chemotherapy and whose cancers have a specific genetic biomarker known as deficient mismatch repair.

Finding the balance between offering support and guidance while at the same time not overwhelming people going through health scares isn’t easy, writes a cancer survivor. He notes that although it may take some practice to get right, it is an important skill for cancer thrivers to get down.

In this episode of the “CURE® Talks Cancer” podcast, Henry Scowcroft discusses his experiences writing a book about his late wife’s cancer journey and offers advice for other caregivers.

Keytruda demonstrated clinical benefit for patients with recurrent and metastatic disease, according to an expert.

Patients with non-small cell lung cancer and a KRAS G12C genetic mutation may benefit from treatment with an inhibitor targeting that mutation, although more research is needed to learn why more patients are not responding to the drug.

Patients with acute myeloid leukemia experience post-traumatic stress disorder symptoms including intrusion, avoidance and hypervigilance one month after diagnosis.

A pediatric oncology nurse offers advice for parents or primary caregivers on how to support their child during cancer treatment.

In recent years, research in treating small cell lung cancer has broadened, bringing emerging therapies like immunotherapy to the forefront.

Certain patients with metastatic renal cell carcinoma may benefit with active surveillance compared with systemic therapy for their management and may also lead to an improved quality of life.

Even with all the recent advances in targeted therapies and immunotherapy drugs, patients with non-small cell lung cancer still need more treatment options. Although it’s early, cell-based therapies have shown some promise, with more research underway.

A cancer survivor describes what “chemo fog” is and writes how many people are now experiencing a double whammy — “pandemic fog.”

After the COVID-19 pandemic caused a delay in cancer screenings, an expert from Karmanos Cancer Hospital and Network urges patients to resume their routine preventative care to avoid any delay in a possible diagnosis.

Active surveillance in sentinel lymph node positive melanoma could delay surgery but may result in the same risk of the cancer coming back.

Median progression-free survival in patients treated with Keytruda was 13.2 months versus 8.3 months with Adcetris, which makes Keytruda an “effective treatment option” for patients in this population who were either ineligible for or relapsed after autologous hematopoietic stem cell transplantation.

On social media, CURE® recently asked its readers to share if they sought a second opinion when discussing their cancer diagnosis and treatment. Here’s what some of them said.

For the patient with a rare cancer, such as sarcoma, finding hope can be especially problematic, writes a cancer surgeon. Making patients hopeful, he writes, about their medical journey is as important as the medical components of treatment.

Despite on-treatment clinical progression, patients treated with Avastin and standard chemotherapy had a median progression-free survival of 11.8 months compared with 8.8 months in those treated with standard chemotherapy alone.

Inlyta alone demonstrates longer progression-free survival compared to Inlyta in combination with carotuximab.

The month of March has not been kind to this person living with metastatic breast cancer. Here, she recalls what it has been like to become the caregiver with cancer.

Enjoy a refreshing kale salad on a sunny afternoon and a savory chickpea curry during an April shower. And don’t forget to treat yourself with kindness — and pudding!

A wife pens a letter to her husband on the first anniversary of his death from cancer about all the things he’s missed — from the big dates to the boring days, such as just watching TV with their dog.